Protagonist Therapeutics (PTGX) Return on Capital Employed (2016 - 2026)

Protagonist Therapeutics has disclosed Return on Capital Employed across 11 years of filings, most recently posting 21.98% for Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 21.98%, up 159.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 21.98% (up 159.0% YoY), and the FY2025 annual result was 23.92%, down 3557.0% from the prior year.
• Return on Capital Employed came in at 21.98% for Q1 2026 at Protagonist Therapeutics, up from 24.73% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 49.76% in Q1 2024 to a low of 66.29% in Q1 2023.
• The 5-year median for Return on Capital Employed is 24.73% (2025), against an average of 20.99%.
• Across the five-year window, Return on Capital Employed surged 11605 bps in 2024 and sank 7333 bps in 2025, its largest moves.
• Protagonist Therapeutics' Return on Capital Employed stood at 56.17% in 2022, then surged by 91 bps to 5.14% in 2023, then soared by 282 bps to 9.36% in 2024, then tumbled by 364 bps to 24.73% in 2025, then grew by 11 bps to 21.98% in 2026.
• The last three Return on Capital Employed figures came in at 21.98% (Q1 2026), 24.73% (Q4 2025), and 26.34% (Q3 2025), per Business Quant data.